ABSTRACT

Osteoporosis is prevalent in elderly women and it may cause dental implant failure. In particular, estrogen deficiency in postmenopausal women leads to higher rates of osteoporosis prevalence. Immune cell-mediated effects involving the development of osteoporosis have been studied previously; however, the role of IL-10-producing regulatory B (B10) cells in osteoporosis is largely unclear. Here, we examined the role of B10 cells in osteoporosis. C57BL/6 mice were subjected to ovariectomy (OVX). Fifteen weeks after OVX surgery, the first molar of the right maxillary was extracted, and twenty-four weeks after OVX surgery, serous progression of osteoporosis was observed in the alveolar bone. Moreover, the proportion of CD19<sup>+</sup>CD5<sup>+</sup>CD1d<sup>high</sup> regulatory B cells, B10, and CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> regulatory T cells from the spleen of OVX mice decreased during the progression of osteoporosis, compared to controls. In contrast to regulatory cells, IL-17-producing Th (Th17) cell levels were increased in OVX mice. Adoptive transfer of B10 cells to OVX mice led to a decrease in Th17 cell abundance and inhibited the development of osteoporosis in the alveolar bone from OVX mice. Thus, our results suggest that B10 cells may help suppress osteoporosis development.

Keywords: Osteoporosis; Ovariectomy; Breg cells; Treg cells; Th17 cells; Adoptive transfer

INTRODUCTION

Osteoporosis is a metabolic bone disorder (1,2) that globally affects >200 million people (3). It is characterized by microarchitectural changes such as decreased bone mass, which increases susceptibility to bone fractures (4). The incidence of osteoporosis increases with age and occurs most frequently in postmenopausal women because of considerably reduced estrogen levels associated with menopause, which indicates that estrogen deficiency is a crucial risk factor for the development of osteoporosis (5-7). In animal models, ovariectomy (OVX) has been used to induce osteoporosis (8).

The contribution of immune cells to the development of OVX-mediated osteoporosis has been shown in previous studies (9,10). T cells are the main contributors to bone loss in estrogen-deficient mice, as OVX increases the production of pro-inflammatory cytokines by T cells to levels that induce increased generation of osteoclasts (11,12). In T cell immunity,
IL-17-producing Th (Th17) cells have controlling effects in inflammatory and other bone diseases (13,14). Th17 cells have been implicated in the pathogenesis of rheumatoid arthritis in mice in which IL-17 deficiency and blockade of IL-17 reduce disease progression (15). Moreover, Th17 cells have been shown to directly control the induction of osteoporosis in OVX mice (9).

Regulatory immune cells can suppress inflammatory bone diseases (13,16). Tregs can exert considerable immunosuppressive effects and inhibit the development of inflammatory diseases (17). Several recent studies confirmed that Treg cells contribute to the inhibition of osteoclastogenesis and bone resorption (18,19), and depletion of Treg cells can exacerbate collagen-induced arthritis in mice (20). Moreover, adoptive transfer of CD4⁺CD25⁺FoxP3⁺T cells shows promising results regarding protection from rheumatoid arthritis (21,22). In addition, Tregs have been shown to directly inhibit osteoclastogenesis by suppressing the expression of receptor activator of NF-κB ligand (RANKL) and M-CSF, leading to increased bone volume (19,23).

Recent studies have found that regulatory B (Breg) cells can contribute to the suppression of inflammation and support the differentiation of Tregs (24,25). IL-10-producing regulatory B (B10) cells, a subset of Breg cells, counteract inflammatory diseases such as collagen-induced arthritis and colitis (26). More importantly, B10 cells alleviate pathogen- or immune stimulator-mediated periodontal inflammation and bone loss (27,28). Although B10 cells exhibit anti-inflammatory effects, the question of whether B10 cells help suppress osteoporosis remains to be answered. We hypothesized that B10 cells may help prevent osteoporosis development in OVX mice, and thus, we conducted experiments to assess the effects of B10 cells on osteoporosis.

**MATERIALS AND METHODS**

**Mice**

C57BL/6 mice (6–8 wk old) were purchased from Shanghai Public Health Clinical Center, China. The mice were housed under specific pathogen-free conditions at 20°C–22°C and 50%–60% humidity; water and a standard rodent chow diet were provided *ad libitum*. This study was approved by the Institutional Animal Care and Use Committee of Shanghai Public Health Clinical Center (approval No. 2018-A050-01), and all experiments were performed according to the respective guidelines. Mice were euthanized by CO₂ inhalation.

**Abs**

Isotype control Abs (IgG1, IgG2a, and IgG2b), CD1d (1B1), CD5 (53-7.3), CD19 (1D2/CD19), CD4 (GK1.5), CD25 (3C7), anti-FoxP3 (MF-14), anti-IL-10 (JES5-16E3), and anti-IL-17A (TC11-18H10.1) were purchased from BioLegend (San Diego, CA, USA).

**Flow cytometry analysis**

Cells were stained with the Fc-block Abs for 15 min (BioLegend). Fluorescence-conjugated Abs were then added and incubated on ice for 20 min. After washing with PBS, the 0.2×10⁶ cells were analyzed on FACS Fortessa (Becton Dickinson, Franklin Lakes, NJ, USA) using FlowJo 8.6 software (Tree Star, San Diego, CA, USA). Isotype control Abs were used for determination of negative cells. Cellular debris and dead cells were excluded by forward- and side-scatter gating and DAPI (Sigma-Aldrich, St. Louis, MO, USA) staining.
OVX and molar tooth extraction
Mice were shaved, and an incision was made to the abdomen after anesthesia by intraperitoneal injection with 100 mg/kg ketamine and 10 mg/kg xylazine solutions. After the ovarian fat pad was removed from the incision site, the oviduct was ligated using sterilized thread, and each ovary was removed using a single cut. Control mice were subjected to the same procedures but without ovary removal. Tooth extraction was performed in all mice 15 weeks after surgery. The first right maxillary molar tooth (M1) was carefully luxated using two 18-gauge needles as levers, with the aid of a 2.5-fold magnifying lens.

Stimulation of B cells and isolation of B10 cells
B10 cells were purified from stimulated B cells using a Breg cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Briefly, B cells from mouse spleen were pre-enriched and stimulated using Porphyromonas gingivalis LPS (5 µg/mL; InvivoGen, San Diego, CA, USA) and CpG-ODN (1 µM; Sangon Biotech, Shanghai, China) for 24 h. Phorbol myristate acetate (PMA, 50 ng/mL; Sigma-Aldrich, St. Louis, MO, USA) and ionomycin (500 ng/mL, Sigma-Aldrich) were then added to the enriched B cell culture medium for the last 5 h of stimulation. B10 cells were isolated using a B10 isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) and were then transferred intravenously into OVX and control mice.

Adoptive transfer of B10 cells
C57BL/6 mice were subjected to OVX or sham surgery. All mice underwent extraction of the first molar of the right maxillary during surgery. B10 cells were isolated from naïve mice and intravenously transferred to OVX mice 15, 18, and 21 wk after surgery at a density of 1×10^6 B10 cells per mouse. The mice were euthanized 24 wk after surgery. Thereafter, the right maxilla was dissected for subsequent micro-computed tomography (CT).

Intracellular cytokine staining
As described previously (29-31), splenocytes were incubated with monensin solution (BioLegend) for 4 h. Cells were stained with surface Abs and were then fixed and permeabilized using Cytofix/Cytoperm buffer (eBioscience, San Diego, CA, USA). After washing with Perm/Wash buffer (eBioscience), the cells were incubated with anti-cytokine Abs in Perm/Wash buffer for 30 min at room temperature. Staining was blocked using Fc blocking Ab, and isotype control IgG were used as negative controls in all experiments. Dead cells were gated out by the Zombie Violet Fixable Viability Kit (BioLegend).

ELISA
Concentrations of IL-17 in mouse sera were measured in triplicate using an ELISA kit (BioLegend).

Micro-CT
Using a micro-CT scanner equipped with a custom software package (Skyscan 1176; Bruker, Billerica, MA, USA), bone specimens were scanned at 70 kVp and 114 µA, at high resolution (9 µm slice thickness), and in three planes. A region of interest distal to the remaining second molar tooth was selected and highlighted on cross-sectional images of each bone specimen. After scanning, three-dimensional images of the region of interest were produced. The bone volume as a proportion of total tissue volume in the region of interest was used as a measure of bone density and was calculated for all treatment groups. Additional trabecular measurements included trabecular thickness (Tra Thick), trabecular separation (Tra Sepra), and trabecular number (Tra Number). Total bone volume was calculated automatically using micro-CT software.
Statistical analyses
Data are shown as means±SEM. A 1- or 2-way ANOVA (Tukey multiple comparison test) and the Mann-Whitney t-test were used for analysis of the data sets. The p-values <0.05 were considered as statistically significant.

RESULTS
Ovariectomy promoted osteoporosis in femur
To evaluate the role of B10 cells in osteoporosis, we first established osteoporosis in mice by OVX. Ovaries were surgically removed from C57BL/6 mice, and changes in body weight were observed for 24 wk. As shown in Fig. 1A, the body weight of mice was significantly increased after OVX surgery compared to controls. Proportions of bone volume per total volume (BV/TV) in femur was significantly decreased in OVX mice compared to that in control mice 24 wk after OVX, which indicated the bone density in the femur of OVX mice was lower than control mice (Fig. 1B and C). In addition, Tra Thick (Fig. 1D) and Tra Number (Fig. 1E) in the femur were also substantially decreased in OVX mice compared to control mice. Tra Sepra (Fig. 1F) in femur was substantially higher in OVX mice than the controls (Fig. 1F). Thus, these results indicated that OVX promoted osteoporosis in mice.
Regulatory immune cells were decreased in OVX mice
We subsequently examined alterations in regulatory immune cell proportions in OVX mice and found that after OVX, the proportion of CD19⁺CD5⁺CD1d<sup>high</sup> Breg cells in the spleen decreased over time (Fig. 2A and Supplementary Fig. 1). Moreover, B10 cells in the spleen were also significantly decreased 21 and 24 wk after OVX (Fig. 2B and Supplementary Fig. 2). Consistently with previous studies, the proportions of CD4⁺CD25⁺FoxP3⁺ Treg cells were also substantially reduced in OVX mice (Fig. 2C and Supplementary Fig. 3). In contrast to regulatory immune cells, Th17 cells were substantially increased in OVX mice (Fig. 2D and Supplementary Fig. 4). Thus, regulatory immune cells, especially Breg and B10 cells, appear to contribute to the development of osteoporosis in OVX mice.

Adoptive transfer of B10 cells prevented the expansion of Th17 cells in OVX mice
We further tested the effects of B10 cell transfer on inflammatory reactions in OVX mice. B10 cells were adoptively transferred to OVX mice 15, 18, and 21 wk after OVX surgery (Fig. 3A). Twenty-four wk after surgery, the proportions of Breg and B10 cells in the spleen were substantially increased following transfer of B10 cells (Fig. 3B and C). In addition, the proportion of Th17 cells in the spleen and serum concentrations of IL-17 were substantially decreased following adoptive transfer of B10 cells into OVX mice (Fig. 3D and E). These data suggested that adoptive transfer of B10 cells downregulated Th17 immune responses in OVX mice.

B10 cell transfer alleviated osteoporosis development in OVX mice
Because adoptive transfer of B10 cells prevented Th17 immune responses, we subsequently examined whether B10 cell transfer would reduce the progression of osteoporosis in OVX mice.

---

**Figure 2.** Alteration of immune cell percentages in the spleen during progression of osteoporosis in OVX mice. C57BL/6 mice were euthanized 12, 15, 18, 21, and 24 weeks after OVX, and spleen cells were analyzed by flow cytometry. (A) Proportion of CD19⁺CD5⁺CD1d<sup>high</sup> Breg cells. (B) Proportion of IL-10-producing cells in Breg cells. (C) CD4⁺CD25⁺FoxP3⁺ Treg cell percentages in the spleen. (D) Proportion of IL-17-producing CD4 T cells in the spleen. The means of six independent samples are shown (n=6, 3 mice for 2 experiments).

* p<0.05, ** p<0.01.
mice. Twenty-four weeks after OVX surgery, mice subjected to adoptive transfer of B10 cells exhibited no decrease in alveolar bone density (Fig. 4A-D). Moreover, reduction of trabecular thickness and number in alveolar bone was inhibited by B10 cell transfer into OVX mice (Fig. 4E and F), and the increased levels of Tra Sepra by OVX were significantly reduced after transfer of B10 cells (Fig. 4G). Thus, these results suggested that adoptive transfer of B10 cells prevented the development of osteoporosis in OVX mice.

**DISCUSSION**

Regulatory immune cells are known to counteract inflammatory diseases (21,22,24,26), and Treg-mediated anti-inflammatory effects have been promising in terms of treatment of inflammation and diseases affecting bone mass in animals and humans (21,22). In the current study, we found that numbers of B10 cells, a subset of Breg cells, were decreased in OVX mice, which indicated that B10 cells may contribute to the development of osteoporosis. Moreover, adoptive transfer of B10 cells into OVX mice suppressed the progression of osteoporosis. These results suggested that, consistent with Tregs, B10 cells also affect the development of osteoporosis.

We found that the number of both Treg and Breg cells decreased during the development of osteoporosis in OVX mice, while Th17 cells increased. The effect of Tregs on inflammatory and bone-affecting diseases has been studied extensively, the delicate balance of Treg-Th17 cells is essential in bone health, as Tregs exhibit protecting effect, whereas Th17 cells involve in bone loss (32); however, the Breg cell type was defined only relatively recently, and its role remains to be further investigated (19). Although both Treg and Breg cells suppress immune system activation (21,24), Breg cells help control T cell-dependent inflammatory responses and induction of Treg differentiation (25). Moreover, CD19$^{+}$CD25$^{high}$ human Breg cells induced increasing of both the cell number and percentage of Tregs, while decreased
Th17 cells population in an *in vitro* conculture system (33). Therefore, transfer of B10 cells into OVX mice may not only suppress Th17 immunity but also induce Treg differentiation. In this study, we focused on the inhibition of osteoporosis by B10 cell transfer; thus, our results do not clearly reveal whether B10 cell transfer can help recover decreased Treg cell levels in OVX mice. Further studies regarding the relationship between B10 and Treg cells during osteoporosis in OVX mice would thus be required.

It has shown that progression of osteoporosis by OVX exhibited increases of CD19 cells in the spleen and bone marrow (34, 35), however the function of the CD19 cells, whether it contributes the development or prevention of osteoporosis, has not been explored. Since B cells increasingly infiltrated in the inflamed tissue, especially autoimmune tissues (36, 37), it may involve in the development of osteoporosis. In contrast to the increased number of

---

Figure 4. B10 cell transfer inhibited the progression of osteoporosis in OVX mice. (A to C) Representative micro-CT 2D cross section of extraction sockets and adjacent molar teeth in (A) control, (B) none transferred OVX and (C) B10 transferred OVX (left-whole samples, white line marks the region of interest; right-higher magnifications of the extraction region, white arrows point out the extraction sites). (D) Proportion of BV/ToV in extraction alveolar bone. (E) Tra Thick is shown. (F) Tra Number in 1 mm is shown. (G) Tra Sepra in alveolar bone (n=6, 3 independent samples from 2 experiments).

*p<0.05, **p<0.01.
total B cells, we found that the percentage of B10 cells was decreased in OVX mice. Since the total number of B cells increased in OVX mice, the number of B10 cells would have decreased relatively. We will further study the changes in inflammatory B cells and B10 cells during development of osteoporosis by OVX.

Increased serum levels of inflammatory cytokines such as IL-1β, IL-6, and TNF-α have potent effects in the induction of osteoclastic bone loss (16). Inflammatory cytokines contribute to osteoclastic bone loss, and effector T cell-mediated cytokines suppress osteoclastogenesis (13,15). IFN-γ is a marker cytokine of Th1 cells and inhibits the formation of osteoclasts (38), and neutralization of interferon γ promotes differentiation of osteoclasts (39). In addition, Th2-mediated IL-4, IL-5, and IL-13 also function as potential inhibitors of osteoclastogenesis (40-42). In contrast to Th1 and Th2 cytokines, IL-17 has been shown to be a critical factor in the pathogenesis of bone loss, osteoporosis, and inflammatory diseases (13-15). The main source of IL-17 is CD4 T cells, which are termed Th17 cells (13). Compared with different types of effector T cells, Th17 cells have been shown to directly contribute to disease onset in estrogen-deficient osteoporosis (43,44). In addition, neutralization of IL-17 by Ab treatment prevents the progression of osteoporosis in OVX mice (44). In the current study, we also found that the proportion of Th17 cells in the spleen increased in a time-dependent manner in OVX mice; however, this effect was reduced by adoptive transfer of B10 cells. Thus, B10 cells may inhibit the differentiation of Th17 cells in OVX mice, thereby decelerating the progression of osteoporosis.

Dental implantation is a common treatment for edentulous patients (45,46). However, accumulating evidence suggests higher failure risks of implant installation in low-density bone tissues (47,48). We found that transfer of B10 cells prevented the development of osteoporosis in the alveolar bone, indicating that B10 cell adoptive transfer may potentially reduce the failure rate of dental implant installation in patients with osteoporosis. Further studies are required to test whether B10 cell transfer improves the efficiency of dental implants in osteoporosis in rats and mice.

ACKNOWLEDGEMENTS

We thank the Shanghai Public Health Clinical Center animal facility for maintaining the animals used in this study. This study was supported by the National Research Foundation of Korea (NRF-2019R1C1C1003334 and NRF-2020R1A6A1A03044512) and the National Natural Science Foundation of China (81874164). Yuhua Wang was supported by the Shanghai Natural Science Foundation (20ZR1431900).

SUPPLEMENTARY MATERIALS

Supplementary Figure 1
Changes of Breg cell percentage in the spleen after OVX. CD19^CD5^CD1d^- Breg cells in spleen were analyzed by flow cytometry 12, 15, 18, 21, and 24 wk after OVX.

Click here to view
Supplementary Figure 2
Changes of B10 cell percentage in the spleen after OVX. Intracellular IL-10 producing CD19+CD5+CD1d+ cells in spleen were analyzed by flow cytometry 12, 15, 18, 21, and 24 wk after OVX.

Click here to view

Supplementary Figure 3
Alteration of CD4+CD25+FoxP3+ Treg cell percentage in the spleen after OVX. Intranuclear expression of FoxP3 and surface expression of CD25 were analyzed in spleen CD4 T cells by flow cytometry 12, 15, 18, 21, and 24 wk after OVX.

Click here to view

Supplementary Figure 4
Change of Th17 cell percentage in the spleen after OVX. Intracellular IL-17 producing cells in spleen CD4 T cells were analyzed by flow cytometry 12, 15, 18, 21, and 24 wk after OVX.

Click here to view

REFERENCES

1. Qaseem A, Forciea MA, McLean RM, Denberg TD. Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. *Ann Intern Med* 2017;166:818-839.

2. Roberts WE, Simmons KE, Garetto LP, DeCastro RA. Bone physiology and metabolism in dental implantology: risk factors for osteoporosis and other metabolic bone diseases. *Implant Dent* 1992;1:11-21.

3. Sözen T, Özsük L, Başaran NÇ. An overview and management of osteoporosis. *Eur J Rheumatol* 2017;4:46-56.

4. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM. The Study of Osteoporotic Fractures Research Group. Bone density at various sites for prediction of hip fractures. *Lancet* 1993;341:72-75.

5. Riggs BL. The mechanisms of estrogen regulation of bone resorption. *J Clin Invest* 2000;106:1203-1204.

6. Tellia SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. *J Steroid Biochem Mol Biol* 2014;142:155-170.

7. Newton-John HF, Morgan DB. The loss of bone with age, osteoporosis, and fractures. *Clin Orthop Relat Res* 1970;71:229-252.

8. Sophocleous A, Idris AI. Rodent models of osteoporosis. *Bonekey Rep* 2014;3:614.

9. Dar HY, Shukla P, Mishra PK, Anupam R, Mondal RK, Tomar GB, Sharma V, Srivastava RK. *Lactobacillus acidophilus* inhibits bone loss and increases bone heterogeneity in osteoporotic mice via modulating Treg-Th17 cell balance. *Bonekey Rep* 2018;8:46-56.

10. Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. *Immunol Rev* 2005;208:207-227.
11. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J, Pacifici R. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α. *J Clin Invest* 2000;106:1229-1237.

12. Zhao R. Immune regulation of osteoclast function in postmenopausal osteoporosis: a critical interdisciplinary perspective. *Int J Med Sci* 2012;9:825-832.

13. Wang M, Tian T, Yu S, He N, Ma D. Th17 and Treg cells in bone related diseases. *Clin Dev Immunol* 2013;2013:203705.

14. Monteleone I, Pallone F, Monteleone G. Th17-related cytokines: new players in the control of chronic intestinal inflammation. *BMC Med* 2011;9:122.

15. Hashimoto M. Th17 in animal models of rheumatoid arthritis. *J Clin Med* 2017;6:73.

16. Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. *Endocr Rev* 2008;29:403-440.

17. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? *Int Immunol* 2009;21:1105-1111.

18. Luo CY, Wang L, Sun C, Li D. Estrogen enhances the functions of CD4+CD25+Foxp3+ regulatory T cells that suppress osteoclast differentiation and bone resorption in vitro. *Cell Mol Immunol* 2011;8:50-58.

19. Fischer L, Herkner C, Kitte R, Dohnke S, Riewaldt J, Kretschmer K, Garbe AI. Foxp3+ regulatory t cells in bone and hematopoietic homeostasis. *Front Endocrinol (Lausanne)* 2019;10:578.

20. Atkinson SM, Hoffmann U, Hamann A, Bach E, Danneskiold-Samsøe NB, Kristiansen K, Serikawa K, Fox B, Kruse K, Haase C, et al. Depletion of regulatory T cells leads to an exacerbation of delayed-type hypersensitivity arthritis in C57BL/6 mice that can be counteracted by IL-17 blockade. *Dis Model Mech* 2016;9:427-440.

21. Oh S, Rankin AL, Caton Al. CD4+CD25+ regulatory T cells in autoimmune arthritis. *Immunol Rev* 2010;233:97-111.

22. Haque M, Fino K, Lei F, Xiong X, Song J. Utilizing regulatory T cells against rheumatoid arthritis. *Front Oncol* 2014;4:209.

23. O’Gradaigh D, Compston JE. T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion. *Rheumatology (Oxford)* 2004;43:122-130.

24. Sokolov AV, Shniadt AA, Lomakin YA. B cell regulation in autoimmune diseases. *Acta Nat 2018;10:11-22.

25. Chien CH, Chiang BL. Regulatory T cells induced by B cells: a novel subpopulation of regulatory T cells. *J Biomed Sci* 2017;24:86.

26. Kalampokis I, Yoshizaki A, Tedder TF. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. *Arthritis Res Ther* 2013;15 Suppl 1:S1.

27. Kwak M, Yu K, Lee PC, Jin JO. *Rehmannia glutinosa* polysaccharide functions as a mucosal adjuvant to induce dendritic cell activation in mediastinal lymph node. *Int J Biol Macromol* 2018;120:1618-1623.

28. Park HB, Lim SM, Hwang I, Zhang W, You S, Jin JO. Cancer immunotherapy using a polysaccharide from *Codium fragile* in a murine model. *OncoImmunology* 2020;9:1772663.
31. Zhang W, Xu L, Park HB, Hwang J, Kwa M, Lee PC, Liang G, Zhang X, Xu J, Jin JO. Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy. Nat Commun 2020;11:1187.

32. Dar HY, Shukla P, Mishra PK, Anupam R, Mondal RK, Tomar GB, Sharma V, Srivastava RK. Lactobacillus acidophilus inhibits bone loss and increases bone heterogeneity in osteoporotic mice via modulating Treg-Th17 cell balance. Bone Rep 2018;8:46-56.

33. Hong M, Liao Y, Liang J, Chen X, Li S, Liu W, Gao C, Zhong Z, Kong D, Deng J, et al. Immunomodulation of human CD19+CD25high regulatory B cells via Th17/Foxp3 regulatory T cells and Th1/Th2 cytokines. Hum Immunol 2019;80:863-870.

34. Qiu X, Gui Y, Zhang N, Xu Y, Li D, Wang L. Effects of Bu-Shen-Ning-Xin Decoction on immune cells of the spleen and bone marrow in ovariectomized mice. Biosci Trends 2016;10:400-409.

35. Onal M, Xiong J, Chen X, Thostenson JD, Almeida M, Manolagas SC, O'Brien CA. Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem 2012;287:29851-29860.

36. Debes GF, McGettigan SE. Skin-associated B cells in health and inflammation. J Immunol 2019;202:1659-1666.

37. Cain D, Kondo M, Chen H, Kelsoe G. Effects of acute and chronic inflammation on B-cell development and differentiation. J Invest Dermatol 2009;129:266-277.

38. Arron JR, Choi Y. Bone versus immune system. Nature 2000;408:535-536.

39. Kotake S, Nanke Y, Mogi M, Kawamoto M, Furuya T, Yago T, Kobashigawa T, Togari A, Kamatani N. IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. Eur J Immunol 2005;35:3353-3363.

40. Palmqvist P, Lundberg P, Persson E, Johansson A, Lundgren I, Lerner UH. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem 2006;281:2414-2429.

41. Wei S, Wang MW, Teitelbaum SL, Ross FP. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-κB and mitogen-activated protein kinase signaling. J Biol Chem 2002;277:6622-6630.

42. Mangashetti LS, Khapli SM, Wani MR. IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-kappa B and Ca2+ signaling. J Immunol 2005;175:917-925.

43. Yuan FL, Li X, Lu WG, Zhao YQ, Li CW, Li JP, Sun JM, Xu BS. Type 17 T-helper cells might be a promising therapeutic target for osteoporosis. Mol Biol Rep 2012;39:771-774.

44. Tyagi AM, Srivastava K, Mansoori MN, Trivedi R, Chattopadhyay N, Singh D. Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. PLoS One 2012;7:e44552.

45. Apse P, Ellen RP, Overall CM, Zarb GA. Microbiota and crevicular fluid collagenase activity in the osseointegrated dental implant sulcus: a comparison of sites in edentulous and partially edentulous patients. J Periodontal Res 1989;24:96-105.

46. Karoussis IK, Kotsovillis S, Fournoumis I. A comprehensive and critical review of dental implant prognosis in periodontally compromised partially edentulous patients. Clin Oral Implants Res 2007;18:669-679.

47. Holahan CM, Koka S, Kennel KA, Weaver AL, Assad DA, Regennitter FI, Kademeni D. Effect of osteoporotic status on the survival of titanium dental implants. Int J Oral Maxillofac Implants 2008;23:905-910.

48. Chen H, Liu N, Xu X, Qu X, Lu E. Smoking, radiotherapy, diabetes and osteoporosis as risk factors for dental implant failure: a meta-analysis. PLoS One 2013;8:e71955.